Jetrea ocriplasmin regulatory update

The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) said Health Canada approved Jetrea ocriplasmin to treat vitreomacular adhesion (VMA). Alcon said it expects Jetrea to be available in Canada "soon," but the exact timing is still being determined. The ophthalmic unit said the list price of Jetrea is C$3,950 ($3,826). Alcon has ex-U.S. commercialization rights to the injectable recombinant microplasmin, a truncated form of the natural human protein plasmin, from ThromboGenics under a 2012 deal (see BioCentury, March 19, 2012). ...